Rachel Kobos

机构：Johnson & Johnson (United States)

发表论文 171 篇 · 总被引 8304 次 · h-index 37

代表论文

• Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study (2023 · Cancer · 被引 87)
• Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation (2023 · Blood Advances · 被引 85)
• Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2025 · New England Journal of Medicine · 被引 69)
• Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study (2024 · Blood · 被引 60)
• Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1 (2023 · Targeted Oncology · 被引 46)
• Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial (2024 · Blood · 被引 31)